No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HOOK HOOKIPA Pharma
- 0.691
- -0.052-7.01%
Trading Jun 17 11:55 ET
68.41MMarket Cap-1440P/E (TTM)
0.739High0.681Low412.80KVolume0.730Open0.744Pre Close288.26KTurnover0.79%Turnover RatioLossP/E (Static)98.95MShares1.13052wk High0.65P/B36.36MFloat Cap0.41052wk Low--Dividend TTM52.59MShs Float20.000Historical High--Div YieldTTM7.79%Amplitude0.410Historical Low0.698Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Raises Target Price to $6
H.C. Wainwright analyst Arthur He CFA maintains $HOOKIPA Pharma(HOOK.US)$ with a buy rating, and adjusts the target price from $5 to $6.According to TipRanks data, the analyst has a success rate of 53
Express News | HOOKIPA Pharma Inc. : H.c. Wainwright Raises Target Price to $6 From $5
HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-
Express News | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
Comments
$HOOKIPA Pharma(HOOK.US$ @Trytosaveabit
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
1
$HOOKIPA Pharma(HOOK.US$ HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
4
2
$HOOKIPA Pharma(HOOK.US$
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
8
$HOOKIPA Pharma(HOOK.US$ First though there is to be additional data come out of the ASCO June 4th! Also Researchers intend to present data from investigator initiated trial of HB-200 W/Chemo, on June 3RD! And now to what i wanted to share from my notes that i took in Janu...
17
3
$HOOKIPA Pharma(HOOK.US$ Shorts piled in here yesterday and just destroyed a beautiful week+ uptrend! MM’s routed almost half of all volume off exchange! Well SS’s Im going to just use as a possible buy opportunity and look for a bounce?
8
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
102415025 : Dropping 7.2 percent